No Data
No Data
These 4 Measures Indicate That Shijiazhuang Yiling Pharmaceutical (SZSE:002603) Is Using Debt Reasonably Well
Eling Pharmaceutical: Semi-Annual Report 2024
Eling Pharmaceutical: Summary of the 2024 Semi-Annual Report
Express News | Yiling Pharmaceutical H1 Net Profit Down 67.0% Y/Y
Shijiazhuang Yiling Pharmaceutical (002603.SZ): The net income in the first half of the year was 0.53 billion yuan, a year-on-year decrease of 66.97%.
On August 27th, Yiling Pharmaceutical (002603.SZ) released its 2024 interim report, with a revenue of 4.604 billion yuan, a year-on-year decrease of 32.19%; a net income attributable to shareholders of the listed company of 0.53 billion yuan, a year-on-year decrease of 66.97%; a net income attributable to shareholders of the listed company taking into account non-recurring gains and losses of 0.505 billion yuan, a year-on-year decrease of 67.24%; and an earnings per share of 0.3175 yuan.
Are Shijiazhuang Yiling Pharmaceutical Co., Ltd.'s (SZSE:002603) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
No Data
No Data